<DOC>
	<DOCNO>NCT00791284</DOCNO>
	<brief_summary>The purpose study 1 ) investigate single-dose pharmacokinetics immediate release ( IR ) paliperidone , oral administration , patient moderate hepatic impairment compare patient normal hepatic function , 2 ) document plasma protein bind disposition enantiomer paliperidone , 3 ) evaluate tolerability safety profile IR paliperidone patient population .</brief_summary>
	<brief_title>A Study Pharmacokinetics Paliperidone Volunteers With Normal Impaired Liver Function</brief_title>
	<detailed_description>This single-dose , parallel-group , open-label , single-center , Phase 1 study immediate release ( IR ) paliperidone patient either normal moderately-impaired hepatic function . The group , consist 10 patient , demographically match respect age , weight , sex , ethnicity . The study consist screen period 3 week open-label , single-dose treatment period ( Days 1 5 ) . On Day 1 , single dose 1 mg Intermediate Release ( IR ) paliperidone oral solution administer fast least 10 hour ; patient continue fast 4 hour follow study drug administration . The 96-hour follow-up consist serial sample collection blood urine pharmacokinetic analysis safety tolerability assessment . Patients remain confined study site 72-hour pharmacokinetics sample consume standard institutional meal study site . Patients release 72-hour sampling , return study site Day 5 96-hour pharmacokinetics sample ; end-of-study procedure perform immediately thereafter . Currently , pharmacokinetic data available oral IR Extended Release ( ER ) formulation paliperidone administer healthy patient patient schizophrenia normal hepatic function . No pharmacokinetic information paliperidone patient hepatic impairment obtain . The target population paliperidone comprise schizophrenic patient . Because patient target population might hepatically impair , pharmacokinetic information population helpful . This single-dose pharmacokinetic study collect information patient normal hepatic function patient moderate hepatic impairment provide clinical dose information/recommendations patient hepatic impairment . Safety tolerability monitor . A single dose 1 mg intermediate release ( IR ) paliperidone oral solution</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients normal hepatic function : Normotensive screening , supine ( 5 minute ) blood pressure range 95 160 mmHg systolic , inclusive , 55 95 mmHg diastolic , inclusive , demographically comparable hepatic impairment group respect age , weight , sex , ethnicity healthy basis prestudy physical examination , medical history , ECG , laboratory result blood biochemistry , hematology , urinalysis perform within 3 week study drug administration . If result biochemistry hematology test urinalysis within laboratory 's reference range , patient include investigator judge deviation clinically significant Patients moderate hepatic impairment : Blood pressure control stable antihypertensive agent , stable hepatic disease laboratory clinical finding support diagnosis hepatic impairment , otherwise healthy basis prestudy physical examination , medical history , ECG , laboratory result blood biochemistry , hematology , urinalysis perform within 3 week study drug administration . Patients control hypertension problem directly associate primary diagnosis hepatic impairment may include . Patients stable , mild , chronic concurrent disease , degenerative joint disease , Type II diabetes , thyroid condition require thyroid replacement therapy surgery , may include . If result biochemistry hematology test urinalysis within laboratory 's reference range , patient include investigator judge deviation clinically significant . Laboratory result related patient 's underlying condition may outside normal range . ( Serum bilirubin , albumin , prothrombin time assess individually ) Total score ChildPugh 's classification 7 9 , inclusive Concomitant medication treat underlying disease state medical condition relate hepatic insufficiency allow . Patients stable dose medication and/or treatment regimen 2 month study , well study . Patients normal hepatic function : Has significant history presence hepatic disease positive serology result hepatitis B surface antigen ( HBsAg ) antihepatitis C virus ( determine multiantigen enzyme immunoassay ) At screening , sustain drop systolic ( &gt; 20 mmHg ) diastolic ( &gt; 10 mmHg ) blood pressure stand least 2 minute associated increase pulse rate &gt; 15 beat per minute Is take , take , prescribed overthecounter drug ( include vitamin herbal supplement ) within 2 week study drug administration ( exception paracetamol , hormonal contraceptive , hormone replacement therapy ) Patients moderate hepatic impairment : Has clinically significant laboratory abnormality except parameter influence hepatic impairment , score 3 4 hepatic encephalopathy determine result Number Connection Test , severe ascites and/or pleural effusion , serology result positive HBsAg , acute exacerbation liver disease , indicate worsen clinical sign hepatic impairment , increase 50 % total bilirubin prothrombin time precede 3 month ( far information available ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>intermediate release ( IR ) Paliperidone</keyword>
</DOC>